123 results
8-K
EX-99.1
GKOS
Glaukos Corporation
20 Feb 25
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
4:10pm
particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient
8-K
EX-99.2
GKOS
Glaukos Corporation
20 Feb 25
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
4:10pm
clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient
8-K
EX-99.1
GKOS
Glaukos Corporation
14 Jan 25
January 2025 Investor Presentation
4:05pm
processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information … ON THE SAME OR FEWER TOPICAL IOP-LOWERING MEDS IN PHASE 3 TRIAL AT 3 YEARS 70% 58% Timolol 0.5% BID
iDose TR: Phase 3 & Phase 2b safety data © 2025 Glaukos
8-K
EX-99.1
GKOS
Glaukos Corporation
15 Nov 24
Investor Presentation November 2024
7:00am
processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information … Excellent Safety PHASE 3 AND PHASE 2B SAFETY DATA FDA APPROVAL: PRESCRIBING SAFETY INFORMATION In controlled studies, the most common ocular adverse
8-K
EX-99.1
yi4qt40p2r
4 Nov 24
Glaukos Announces Third Quarter 2024 Financial Results
4:10pm
8-K
EX-99.2
aw1 k2skhapl5ewa
4 Nov 24
Glaukos Announces Third Quarter 2024 Financial Results
4:10pm
8-K
EX-99.1
ja0nhmtl tac3
9 Aug 24
Investor Presentation August 2024
7:00am
8-K
EX-99.1
9nseu59 e1
31 Jul 24
Glaukos Announces Second Quarter 2024 Financial Results
4:10pm
8-K
EX-99.2
4l2f4bif
31 Jul 24
Glaukos Announces Second Quarter 2024 Financial Results
4:10pm
8-K
EX-99.1
qkmweolgoa9ak0yu86
14 Jun 24
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
7:10am
SD
EX-1.01
5cbfsgx kbi1pgv
30 May 24
Conflict minerals disclosure
4:45pm
8-K
EX-99.1
jcry68
20 May 24
Investor Presentation May 2024
7:00am
8-K
EX-99.2
035dq max00
1 May 24
Glaukos Announces First Quarter 2024 Financial Results
4:10pm
8-K
EX-99.1
mav00fs4d2g2 ic8
1 May 24
Glaukos Announces First Quarter 2024 Financial Results
4:10pm
8-K
EX-99.1
m67ph3tktya hxa
28 Feb 24
Investor Presentation February 2024
7:00am
8-K
EX-99.1
r5uj9
21 Feb 24
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm